Suppression of Foxo3-Gatm by miR-132-3p Accelerates Cyst Formation by Up-Regulating ROS in Autosomal Dominant Polycystic Kidney Disease |
Choi, Seonju
(Department of Biological Sciences and Research Institute of Women's Health, Sookmyung Women's University)
Kim, Do Yeon (Department of Biological Sciences and Research Institute of Women's Health, Sookmyung Women's University) Ahn, Yejin (Department of Biological Sciences and Research Institute of Women's Health, Sookmyung Women's University) Lee, Eun Ji (Department of Biological Sciences and Research Institute of Women's Health, Sookmyung Women's University) Park, Jong Hoon (Department of Biological Sciences and Research Institute of Women's Health, Sookmyung Women's University) |
1 | Ham, H. J., Park, J. W. and Bae, Y. S. (2019) Defect of SIRT1-FoxO3a axis is associated with the production of reactive oxygen species during protein kinase CK2 downregulation-mediated cellular senescence and nematode aging. BMB Rep. 52, 265-270. DOI |
2 | Humm, A., Fritsche, E., Steinbacher, S. and Huber, R. (1997) Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis. EMBO J. 16, 3373-3385. DOI |
3 | Igarashi, P. and Somlo, S. (2007) Polycystic kidney disease. J. Am. Soc. Nephrol. 18, 1371-1373. DOI |
4 | Ishimoto, Y., Inagi, R., Yoshihara, D., Kugita, M., Nagao, S., Shimizu, A., Takeda, N., Wake, M., Honda, K., Zhou, J. and Nangaku, M. (2017) Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol. Cell. Biol. 37, e00337-17. |
5 | Kim, D. Y., Woo, Y. M., Lee, S., Oh, S., Shin, Y., Shin, J. O., Park, E. Y., Ko, J. Y., Lee, E. J., Bok, J., Yoo, K. H. and Park, J. H. (2019) Impact of miR-192 and miR-194 on cyst enlargement through EMT in autosomal dominant polycystic kidney disease. FASEB J. 33, 2870-2884.. DOI |
6 | Li, L., Kang, H., Zhang, Q., D'Agati, V. D., Al-Awqati, Q. and Lin, F. (2019) FoxO3 activation in hypoxic tubules prevents chronic kidney disease. J. Clin. Invest. 129, 2374-2389. DOI |
7 | Li, Y., Li, J., Woo, Y. M., Shen, Z., Yao, H., Cai, Y., Lin, M. C. and Poon, W. S. (2017) Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model. BMC Cancer 17, 126. DOI |
8 | Woo, Y. M., Kim, D. Y., Koo, N. J., Kim, Y. M., Lee, S., Ko, J. Y., Shin, Y., Kim, B. H., Mun, H., Choi, S., Lee, E. J., Shin, J. O., Park, E. Y., Bok, J. and Park, J. H. (2017) Profiling of miRNAs and target genes related to cystogenesis in ADPKD mouse models. Sci. Rep. 7, 14151. DOI |
9 | Reichold, M., Klootwijk, E. D., Reinders, J., Otto, E. A., Milani, M., Broeker, C., Laing, C., Wiesner, J., Devi, S., Zhou, W., Schmitt, R., Tegtmeier, I., Sterner, C., Doellerer, H., Renner, K., Oefner, P. J., Dettmer, K., Simbuerger, J. M., Witzgall, R., Stanescu, H. C., Dumitriu, S., Iancu, D., Patel, V., Mozere, M., Tekman, M., Jaureguiberry, G., Issler, N., Kesselheim, A., Walsh, S. B., Gale, D. P., Howie, A. J., Martins, J. R., Hall, A. M., Kasgharian, M., O'Brien, K., Ferreira, C. R., Atwal, P. S., Jain, M., Hammers, A., Charles-Edwards, G., Choe, C. U., Isbrandt, D., Cebrian-Serrano, A., Davies, B., Sandford, R. N., Pugh, C., Konecki, D. S., Povey, S., Bockenhauer, D., Lichter-Konecki, U., Gahl, W. A., Unwin, R. J., Warth, R. and Kleta, R. (2018) Glycine amidinotransferase (GATM), renal fanconi syndrome, and kidney failure. J. Am. Soc. Nephrol. 29, 1849-1858. DOI |
10 | Andries, A., Daenen, K., Jouret, F., Bammens, B., Mekahli, D. and Van Schepdael, A. (2019) Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression? Pediatr. Nephrol. 34, 993-1008. DOI |
11 | Zhang, J., Wang, X., Vikash, V., Ye, Q., Wu, D., Liu, Y. and Dong, W. (2016) ROS and ROS-mediated cellular signaling. Oxid. Med. Cell. Longev. 2016, 4350965. DOI |
12 | Marinkovic, D., Zhang, X., Yalcin, S., Luciano, J. P., Brugnara, C., Huber, T. and Ghaffari, S. (2007) Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J. Clin. Invest. 117, 2133-2144. DOI |
13 | Kim, J. E., Hong, J. W., Lee, H. S., Kim, W., Lim, J., Cho, Y. S. and Kwon, H. J. (2018) Hsa-miR-10a-5p downregulation in mutant UQCRB-expressing cells promotes the cholesterol biosynthesis pathway. Sci. Rep. 8, 12407. DOI |
14 | Klotz, L. O., Sanchez-Ramos, C., Prieto-Arroyo, I., Urbanek, P., Steinbrenner, H. and Monsalve, M. (2015) Redox regulation of FoxO transcription factors. Redox Biol. 6, 51-72. DOI |
15 | Kops, G. J., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W., Coffer, P. J., Huang, T. T., Bos, J. L., Medema, R. H. and Burgering, B. M. (2002) Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316-321. DOI |
16 | Lin, F. (2020) Molecular regulation and function of FoxO3 in chronic kidney disease. Curr. Opin. Nephrol. Hypertens 29, 439-445. DOI |
17 | Liu, J. W., Chandra, D., Rudd, M. D., Butler, A. P., Pallotta, V., Brown, D., Coffer, P. J. and Tang, D. G. (2005) Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS. Oncogene 24, 2020-2031. DOI |
18 | Mochizuki, T., Wu, G., Hayashi, T., Xenophontos, S.L., Veldhuisen, B., Saris, J. J., Reynolds, D. M., Cai, Y., Gabow, P. A., Pierides, A., Kimberling, W. J., Breuning, M. H., Deltas, C. C., Peters, D. J. and Somlo, S. (1996) PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272, 1339-1342. DOI |
19 | Peters, D. J. and Sandkuijl, L. A. (1992) Genetic heterogeneity of poly-cystic kidney disease in Europe. Contrib. Nephrol. 97, 128-139. DOI |
20 | Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J. and Czerwiec, F. S.; TEMPO 3:4 Trial Investigators (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407-2418. DOI |
21 | Tzivion, G., Dobson, M. and Ramakrishnan, G. (2011) FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta 1813, 1938-1945. DOI |
22 | van der Horst, A. and Burgering, B. M. (2007) Stressing the role of FoxO proteins in lifespan and disease. Nat. Rev. Mol. Cell Biol. 8, 440-450. DOI |
23 | Woo, Y. M., Bae, J. B., Oh, Y. H., Lee, Y. G., Lee, M. J., Park, E. Y., Choi, J. K., Lee, S., Shin, Y., Lyu, J., Jung, H. Y., Lee, Y. S., Hwang, Y. H., Kim, Y. J. and Park, J. H. (2014) Genome-wide methylation profiling of ADPKD identified epigenetically regulated genes associated with renal cyst development. Hum. Genet. 133, 281-297. DOI |
24 | Ferber, E. C., Peck, B., Delpuech, O., Bell, G. P., East, P. and Schulze, A. (2012) FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ. 19, 968-979. DOI |
25 | Bijkerk, R., de Bruin, R. G., van Solingen, C., van Gils, J. M., Duijs, J. M., van der Veer, E. P., Rabelink, T. J., Humphreys, B. D. and van Zonneveld, A. J. (2016) Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation. Kidney Int. 89, 1268-1280. DOI |
26 | Calnan, D. R. and Brunet, A. (2008) The FoxO code. Oncogene 27, 2276-2288. DOI |
27 | Calvo, S. E., Clauser, K. R. and Mootha, V. K. (2016) MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res. 44, D1251-D1257. DOI |
28 | Hagenbuchner, J., Kuznetsov, A., Hermann, M., Hausott, B., Obexer, P. and Ausserlechner, M. J. (2012) FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3. J. Cell Sci. 125, 1191-1203. DOI |
29 | Fujiki, T., Ando, F., Murakami, K., Isobe, K., Mori, T., Susa, K., Nomura, N., Sohara, E., Rai, T. and Uchida, S. (2019) Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation. Sci. Rep. 9, 9245. DOI |
30 | Gansevoort, R. T., Arici, M., Benzing, T., Birn, H., Capasso, G., Covic, A., Devuyst, O., Drechsler, C., Eckardt, K. U., Emma, F., Knebelmann, B., Le Meur, Y., Massy, Z. A., Ong, A. C., Ortiz, A., Schaefer, F., Torra, R., Vanholder, R., Wiecek, A., Zoccali, C. and Van Biesen, W. (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol. Dial. Transplant. 31, 337-348. DOI |